Comparative Pharmacology
Head-to-head clinical analysis: CRESTOR versus ZYPITAMAG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRESTOR versus ZYPITAMAG.
CRESTOR vs ZYPITAMAG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol.
ZYPITAMAG (pitavastatin magnesium) is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to reduced intracellular cholesterol and upregulation of LDL receptors.
Oral, 5-40 mg once daily. Initial dose typically 10-20 mg; max 40 mg.
2-4 mg orally once daily, at any time of day, with or without food.
None Documented
None Documented
The terminal elimination half-life is approximately 19 hours (range 13–20 hours). This long half-life allows once-daily dosing and provides sustained HMG-CoA reductase inhibition.
Terminal elimination half-life: 12 hours (range 10-14 h) in healthy subjects; supports once-daily dosing
Approximately 90% of rosuvastatin is eliminated in feces (as unchanged drug and metabolites), and about 10% is excreted in urine (mainly as unchanged drug). Biliary excretion is the primary route for elimination of metabolites.
Primarily renal (93% as unchanged pitavastatin and metabolites) via active tubular secretion; fecal (5%)
Category C
Category C
Statin
Statin